![\"\"](\"https:\/\/semmelweis.hu\/esk\/files\/2024\/11\/abra_recenzio6-1024x630.png\")
<\/p>\n<\/p>\n
Charlotte Laniece Delaunay, PhD<\/em>\u00a0(Epiconcept), A h\u00e1ziorvosok r\u00e9szv\u00e9tel\u00e9vel zajl\u00f3 kutat\u00e1s sor\u00e1n az XBB.1.5 vakcin\u00e1k eredm\u00e9nyess\u00e9g\u00e9t (VE) vizsg\u00e1ltuk a t\u00fcnetekkel j\u00e1r\u00f3 SARS-CoV-2 fert\u0151z\u00e9ssel szemben a 65 \u00e9ves \u00e9s ann\u00e1l id\u0151sebb betegcsoportban. A vizsg\u00e1latot teszt-negat\u00edv m\u00f3dszerrel v\u00e9gezt\u00fck, Eur\u00f3pa t\u00f6bb orsz\u00e1g\u00e1nak r\u00e9szv\u00e9tel\u00e9vel a 2023\/2024. \u00e9vi l\u00e9g\u00fati szezonban, a JN.1 alvari\u00e1ns \u00e1ltal domin\u00e1lt id\u0151szakban.<\/p>\n A betegeket az akut l\u00e9g\u00fati fert\u0151z\u00e9s (ARI) esetdefin\u00edci\u00f3 alapj\u00e1n vont\u00e1k be a h\u00e1ziorvosok a vizsg\u00e1latba, a l\u00e9g\u00fati mint\u00e1k vizsg\u00e1lata pedig RT-PCR m\u00f3dszerrel t\u00f6rt\u00e9nt. A v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9gi vizsg\u00e1latban a laborat\u00f3riumi vizsg\u00e1lattal SARS-CoV-2 pozit\u00edvk\u00e9nt meger\u0151s\u00edtett egy\u00e9nek esetk\u00e9nt, a negat\u00edv eredm\u00e9nyt ad\u00f3 egy\u00e9nek kontrollk\u00e9nt ker\u00fcltek azonos\u00edt\u00e1sra. A becsl\u00e9seket a vizsg\u00e1lati helysz\u00ednre, \u00e9letkorra, nemre, a m\u00e1r fenn\u00e1ll\u00f3 kr\u00f3nikus \u00e1llapotokra \u00e9s a t\u00fcnetek megjelen\u00e9s\u00e9nek id\u0151pontj\u00e1ra korrig\u00e1ltuk. A vizsg\u00e1latba \u00f6sszesen 220 esetet \u00e9s 1733 kontrollt vontunk be.<\/p>\n A VE 48% (95% CI: 12\u201371) volt azokn\u00e1l, akikn\u00e9l 1-5 h\u00e9ttel az olt\u00e1st k\u00f6vet\u0151en jelentkeztek a t\u00fcnetek, 23 % (95% CI: \u221211\u201348) volt azokn\u00e1l, akikn\u00e9l 6-11 h\u00e9ttel \u00e9s 5% (95% CI: \u221292\u201356) azokn\u00e1l az oltottakn\u00e1l, akik a t\u00fcnetek megjelen\u00e9s\u00e9t megel\u0151z\u0151 12 h\u00e9tben vagy ann\u00e1l r\u00e9gebben r\u00e9szes\u00fcltek az olt\u00e1sban.<\/p>\n Az eredm\u00e9nyek r\u00e1mutattak arra, hogy az XBB.1.5 v\u00e9d\u0151olt\u00e1s r\u00f6vid \u00e9s m\u00e9rs\u00e9kelt v\u00e9delmet ny\u00fajtott a JN.1 t\u00fcnetes fert\u0151z\u00e9ssel szemben, \u00e9s ez k\u00f6zel azonos m\u00e9rt\u00e9k\u0171 az ugyanebben a popul\u00e1ci\u00f3ban v\u00e9gzett XBB vari\u00e1nssal szembeni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g\u00e9vel.<\/p>\n Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023\u20131 March 2024<\/strong><\/span><\/p>\n We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged \u2265\u200965\u2009years during the 2023\/2024 JN.1 lineage-predominant period in a European multi-country test-negative case\u2013control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12\u201371), 23% (95% CI: \u221211\u201348) and 5% (95% CI: \u221292\u201356) among those with symptom onset 1\u20135, 6\u201311, and \u2265\u200912\u2009weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.<\/p>\n \u00a0<\/p>\n Merdrignac, L., Laniece Delaunay, C., Verdasca, N., Vega-Piris, L., O’Donnell, J., S\u00e8ve, N., Trobajo-Sanmart\u00edn, C., Buda, S., Hooiveld, M., Rodrigues, A., T\u00fari, G., Latorre-Margalef, N., Mlinari\u0107, I., Lazar, M., Maurel, M., Castrillejo, D., Bennett, C., Rameix-Welti, M.-A., Mart\u00ednez-Baz, I., D\u00fcrrwald, R., Meijer, A., Melo, A., Oroszi, B., Hagey, T., Kure\u010di\u0107 Filipovi\u0107, S., Dijkstra, F., Gomez, V., Bacci, S., Kaczmarek, M., Kissling, E. and (2024), Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023\u20131 March 2024. Influenza Other Respi Viruses, 18: e70009. https:\/\/doi.org\/10.1111\/irv.70009<\/p>\n https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.70009<\/strong><\/p>\n K\u00e9sz\u00edtette az Charlotte Laniece Delaunay, PhD\u00a0(Epiconcept), Gerg\u0151 T\u00fari, MSc\u00a0(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest), Marine Maurel, MSc\u00a0(Epiconcept), Beatrix Oroszi, PhD\u00a0(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest), Esther\u00a0Kissling,\u00a0MSc\u00a0(Epiconcept) and the VEBIS Primary Care Vaccine Effectiveness Group A JN.1 alvari\u00e1ns \u00e1ltal domin\u00e1ns id\u0151szakban a t\u00fcnetekkel j\u00e1r\u00f3 SARS-CoV-2 fert\u0151z\u00e9ssel …<\/p>\n","protected":false},"author":102284,"featured_media":1723,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[11],"class_list":["post-1722","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok","tag-2024-ev"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=1722"}],"version-history":[{"count":2,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1722\/revisions"}],"predecessor-version":[{"id":1725,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1722\/revisions\/1725"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/1723"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=1722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=1722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=1722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nGerg\u0151 T\u00fari, MSc\u00a0<\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
\nMarine Maurel, MSc\u00a0<\/em>(Epiconcept),
\nBeatrix Oroszi, PhD\u00a0<\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
\nEsther\u00a0Kissling,\u00a0MSc\u00a0<\/em>(Epiconcept)
\nand the VEBIS Primary Care Vaccine Effectiveness Group<\/em><\/p>\nA JN.1 alvari\u00e1ns \u00e1ltal domin\u00e1ns id\u0151szakban a t\u00fcnetekkel j\u00e1r\u00f3 SARS-CoV-2 fert\u0151z\u00e9ssel szembeni XBB 1.5. vakcin\u00e1k eredm\u00e9nyess\u00e9ge az id\u0151s lakoss\u00e1g k\u00f6r\u00e9ben (Eur\u00f3pai VEBIS h\u00e1ziorvosi multicentrikus vizsg\u00e1lat, 2023. november 20 \u2013 2024. m\u00e1rcius 1.)<\/strong><\/span><\/h2>\n
Abstract<\/strong><\/span><\/h3>\n
![\"\"](\"https:\/\/semmelweis.hu\/esk\/files\/2024\/02\/se_esk_logo_fekvo_sotet-400x90.png\"){kind=logo}
\u00a0<\/em><\/span><\/p>\n![\"\"](\"https:\/\/semmelweis.hu\/esk\/files\/2024\/10\/Nemzeti_Labor__logo-400x167.jpg\"){kind=logo}
<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n![\"\"](\"https:\/\/semmelweis.hu\/esk\/files\/2023\/11\/RRF-1024x118.jpg\")
<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"